As the market for bispecific antibody therapeutics continues to soar, novel solutions are required to overcome challenges in producing these next-generation molecules. In this presentation, our expert demonstrates how bYlok® uses a close-to-nature design solution to deliver high accurate heavy-light chain pairing efficiencies and improved manufacturability, with no observed effect on immunogenicity.
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.